Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

4D Molecular Therapeutics Inc (NQ: FDMT )

21.26 +1.03 (+5.09%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 27, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 218,052
Open 20.23
Bid (Size) 21.26 (1)
Ask (Size) 23.12 (2)
Prev. Close 20.23
Today's Range 19.87 - 21.30
52wk Range 5.320 - 26.49
Shares Outstanding 32,392,378
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
4D Molecular Therapeutics Announces Updates on Clinical Pipeline and Additional Preclinical Programs
From 4D Molecular Therapeutics, Inc.
Via Globe NewsWire
How Is The Market Feeling About 4D Molecular Therapeutics?
4D Molecular Therapeutics's (NASDAQ:FDMT) short percent of float has fallen 15.19% since its last report. The company recently reported that it has 2.29 million shares sold short, which is 8.82% of all... 
Via Benzinga

Performance

YTD
+3.00%
+3.00%
1 Month
-3.63%
-3.63%
3 Month
+145.50%
+145.50%
6 Month
+135.96%
+135.96%
1 Year
+45.12%
+45.12%

More News

Read More
4D Molecular Therapeutics to Participate in the Upcoming Evercore ISI HealthCONx 2022 Conference
From 4D Molecular Therapeutics, Inc.
Via Globe NewsWire
2 Biotech Stocks That Can Rocket Higher in 2023, According to Wall Street
Via The Motley Fool
Expert Ratings for 4D Molecular Therapeutics
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Why American Eagle Outfitters Shares Climbed Over 18%; Here Are 78 Biggest Movers From Yesterday
Via Benzinga
HC Wainwright Creates Bullish Pitch On 4D Molecular Citing 'Broader Systemic Potential'
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 18, 2022
Via Benzinga
Cramer On This Stock Down 65% Year-To-Date: 'I Do Believe It's Bottoming, But I Don't Know What Gets It Higher'
Via Benzinga
Sea, UiPath, J&J Snack Foods And Other Big Gainers From Tuesday
Via Benzinga
Why Foresight Autonomous Shares Jumped 33%; Here Are 83 Biggest Movers From Yesterday
Via Benzinga
Why Fast Radius Shares Plunged Around 48%; Here Are 103 Biggest Movers From Yesterday
Via Benzinga
Why Opiant Pharmaceuticals Shares Are Trading Higher By 115%? Here Are 67 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Dow Surges More Than 300 Points After Producer Prices Increase Less Than Expected
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
4D Molecular Therapeutics Shares Jump After Early Data From Wet Age-Related Macular Degeneration Trial
Via Benzinga
4D Molecular Therapeutics Announces Interim Clinical Data from On-going Phase 1/2 Clinical Trial of Intravitreal 4D-150 for Wet Age-Related Macular Degeneration (wet AMD)
From 4D Molecular Therapeutics, Inc.
Via Globe NewsWire
4D Molecular Therapeutics Interim Clinical Data from the On-going Phase 1/2 Clinical Trial of 4D-150 for Wet AMD to be Released Monday, November 14, 2022
From 4D Molecular Therapeutics, Inc.
Via Globe NewsWire
Why Tattooed Chef Shares Dipped Around 15%; Here Are 95 Biggest Movers From Friday
Via Benzinga
4D Molecular Therapeutics Reports Third Quarter 2022 Financial Results
From 4D Molecular Therapeutics, Inc.
Via Globe NewsWire
4D Molecular Therapeutics Announces Interim Clinical Data from Phase 1/2 Clinical Trial of 4D-710 for Cystic Fibrosis Lung Disease at NACFC 2022
From 4D Molecular Therapeutics, Inc.
Via Globe NewsWire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
4D Molecular Therapeutics Interim Clinical Data from the On-going Phase 1/2 Clinical Trial of 4D-710 for Cystic Fibrosis Lung Disease to be Presented at NACFC 2022
From 4D Molecular Therapeutics, Inc.
Via Globe NewsWire
Kiora Pharma is Starting Human Trials of a Novel Treatment That Could Restore Vision In Patients With Inherited Blindness
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.